Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
暂无分享,去创建一个
[1] D W Dickson,et al. Neuropathology of Alzheimer's disease and other dementias. , 2001, Clinics in geriatric medicine.
[2] K. Zahs,et al. Probing the Biology of Alzheimer's Disease in Mice , 2010, Neuron.
[3] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[4] J. Cummings,et al. Alzheimer's disease , 1998, Neurology.
[5] Beat Meier,et al. Prions , 2010 .
[6] Y. Stern,et al. Diabetes mellitus and the risk of dementia , 1999, Neurology.
[7] J. Holton,et al. Genetic alterations of the BRI2 gene: familial British and Danish dementias. , 2006, Brain pathology.
[8] S. Younkin,et al. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition , 2001, Neurobiology of Aging.
[9] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[10] R. Mayeux,et al. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly , 1999, Neurology.
[11] Dominic M. Walsh,et al. Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.
[12] R. Green,et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial , 2007, Neurology.
[13] J. Haines,et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .
[14] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[15] M. Albert,et al. Amnestic MCI or prodromal Alzheimer's disease? , 2004, The Lancet Neurology.
[16] G. Halliday,et al. Variations in the neuropathology of familial Alzheimer’s disease , 2009, Acta Neuropathologica.
[17] Tw. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002, The Lancet.
[18] Philip S. Insel,et al. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. , 2011, Archives of neurology.
[19] T. Golde,et al. The Aβ Hypothesis: Leading Us to Rationally‐Designed Therapeutic Strategies for the Treatment or Prevention of Alzheimer Disease , 2005, Brain pathology.
[20] R. Nitsch,et al. Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.
[21] M. Stoeckli,et al. Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition , 2008, Journal of Pharmacology and Experimental Therapeutics.
[22] J. Morrison,et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.
[23] A D Roses,et al. Apolipoprotein E and Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[24] F. Schmitt,et al. Designing a large prevention trial: statistical issues , 2004, Statistics in medicine.
[25] Lewis H Kuller,et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. , 2008, JAMA.
[26] S. Leurgans,et al. The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.
[27] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[28] M. Ball,et al. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories: Concurrences and Cautions , 1997, Neurobiology of Aging.
[29] C. Meinert,et al. Alzheimer's Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results , 2009, Alzheimer's & Dementia.
[30] K. Davis,et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.
[31] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[32] Scott A. Small,et al. Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.
[33] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[34] Nicola Vanacore,et al. Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials , 2007, PLoS medicine.
[35] S. Younkin. The role of A beta 42 in Alzheimer's disease. , 1998, Journal of physiology, Paris.
[36] P. Tariot,et al. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. , 2010, Biomarkers in medicine.
[37] G. Donnan,et al. 1,026 Experimental treatments in acute stroke , 2006, Annals of neurology.
[38] R. Collins,et al. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial , 2002 .
[39] John Q Trojanowski,et al. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs , 2004, Nature Medicine.
[40] K. Ashe. Learning and memory in transgenic mice modeling Alzheimer's disease. , 2001, Learning & memory.
[41] C. Ross,et al. Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.
[42] Mary Sano,et al. Current Alzheimer's disease clinical trials: Methods and placebo outcomes , 2009, Alzheimer's & Dementia.
[43] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[44] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[45] H. Brodaty,et al. ALZHEIMER'S DISEASE INTERNATIONAL , 1997, International journal of geriatric psychiatry.
[46] David A. Bennett,et al. Postmortem Indices Linking Risk Factors to Cognition: Results From the Religious Order Study and the Memory and Aging Project , 2006, Alzheimer disease and associated disorders.
[47] Stanley B. Prusiner,et al. Nobel Lecture: Prions , 1998 .
[48] D. Murphy,et al. The Women's Health Initiative Memory Study: findings and implications for treatment , 2005, The Lancet Neurology.
[49] J. Hardy,et al. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.
[50] C. Hennekens,et al. Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. , 2000, Annals of epidemiology.
[51] A. Fagan,et al. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.
[52] Linus Jönsson,et al. The worldwide societal costs of dementia: Estimates for 2009 , 2010, Alzheimer's & Dementia.
[53] J. Dungan. Ginkgo biloba for Preventing Cognitive Decline in Older Adults: A Randomized Trial , 2010 .
[54] F. Volkmar. What is a "placebo controlled" study? , 2001, Journal of autism and developmental disorders.
[55] B. Vellas,et al. The GuidAge study , 2006, Neurology.
[56] J. Morris,et al. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.
[57] E. Barrett-Connor,et al. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. , 2002, The American journal of medicine.
[58] Mark E. Schmidt,et al. The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.
[59] A. Fagan,et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[60] S. Weggen,et al. Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity* , 2003, Journal of Biological Chemistry.
[61] M. Brown,et al. A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.
[62] A. Coats. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .
[63] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[64] S. Younkin. The role of Aβ42 in Alzheimer's disease , 1998, Journal of Physiology-Paris.
[65] Todd E. Golde,et al. Targeting Aβ and tau in Alzheimer's disease, an early interim report , 2010, Experimental Neurology.
[66] C. Jack,et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.
[67] J. Schneider,et al. Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.
[68] S. Weggen,et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. , 2003, The Journal of biological chemistry.
[69] R. Katz,et al. Biomarkers and surrogate markers: An FDA perspective , 2004, NeuroRX.
[70] Mark A Mintun,et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. , 2009, Archives of neurology.
[71] C. Meinert,et al. Double placebo design in a prevention trial for Alzheimer's disease. , 2002, Controlled clinical trials.
[72] D. Price,et al. Mutant genes in familial Alzheimer's disease and transgenic models. , 1998, Annual review of neuroscience.
[73] Roy W Jones. Dimebon disappointment , 2010, Alzheimer's Research & Therapy.
[74] K. Blennow. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
[75] J. Trojanowski,et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.
[76] J. Cummings,et al. Disease-modifying therapies in Alzheimer’s disease ⁎ ⁎ EDITOR’S NOTE: The Journal intended to include this article in the January 2008 supplement, “Leon Thal Symposium on Prevention of Dementia.” , 2008, Alzheimer's & Dementia.
[77] Mary Sano,et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.
[78] A. Roses. Genetic testing for Alzheimer disease. Practical and ethical issues. , 1997, Archives of neurology.